Intervention

Erlotinib Hydrochloride

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 20 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20

Recruiting0

Common conditions25

Lead sponsors shown7

Clinical trials

20 shown

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerNCT03137771 · 2017-04-07

ACTIVE_NOT_RECRUITING

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLCNCT03074864 · 2017-02-27

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerNCT02535338 · 2016-04-11

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11

ACTIVE_NOT_RECRUITING

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionNCT02134886 · 2014-07-01

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · 2014-06-16

Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung CancerNCT01857271 · 2013-11-01

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerNCT01866410 · 2013-05-20

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerNCT01708954 · 2013-02-13

ACTIVE_NOT_RECRUITING

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsNCT01532089 · 2012-03-16

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyNCT01294306 · 2011-02-01

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerNCT01193881 · 2010-08-01

Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the LungNCT01013831 · 2009-10-01

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT00738881 · 2008-10-01

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung CancerNCT00950365 · 2006-04-01

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryNCT00254384 · 2005-10-05

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung CancerNCT00126581 · 2005-08-15

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerNCT00096265 · 2004-10-06

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast CancerNCT00054132 · 2002-12-01

Common conditions

Recurrent Non-Small Cell Lung Carcinoma8 Stage IV Non-Small Cell Lung Cancer5 Stage IIIB Non-Small Cell Lung Cancer4 Stage IV Lung Non-Small Cell Cancer AJCC v74 Lung Adenocarcinoma3 Recurrent Lung Non-Small Cell Carcinoma3 Stage IIIA Non-Small Cell Lung Cancer3 Bronchioloalveolar Carcinoma2 Large Cell Lung Carcinoma2 Lung Non-Squamous Non-Small Cell Carcinoma2 Recurrent Squamous Cell Lung Carcinoma2 Stage IB Lung Non-Small Cell Carcinoma AJCC v72 Stage IIA Lung Non-Small Cell Carcinoma AJCC v72 Stage IIB Lung Non-Small Cell Carcinoma AJCC v72 Stage IIIA Lung Non-Small Cell Cancer AJCC v72 Stage IIIB Lung Non-Small Cell Cancer AJCC v72 Stage IV Non-Small Cell Lung Cancer AJCC v72 Stage IV Squamous Cell Lung Carcinoma AJCC v72 Adenosquamous Lung Carcinoma1 Dysplasia1 EGFR Exon 19 Deletion Mutation1 EGFR NP_005219.2:p.L858R1 Epidermal Growth Factor Receptor1 HIV Infection1 Lung Adenosquamous Carcinoma1

Leading sponsors

National Cancer Institute (NCI) 12 Albert Einstein College of Medicine 2 SWOG Cancer Research Network 2 Academic and Community Cancer Research United 1 Guangdong Provincial People's Hospital 1 M.D. Anderson Cancer Center 1 NRG Oncology 1

Trial status mix

COMPLETED9

TERMINATED7

ACTIVE_NOT_RECRUITING3

UNKNOWN1

Phase mix

PHASE212

PHASE15

PHASE35

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.